TranScrip Partners opens Hong Kong office

UK-headquartered contract organisation TranScrip Partners has opened a new office in Hong Kong. This follows recent openings in Australia and the US and is underpinned by the continuing increase of contracts in the Asia-Pacific region.

The company supports biopharmaceutical product development and life-cycle management across a client base of over 80 companies in Europe, US, India, Australia, Singapore and China. Services include development and market positioning strategies for early molecules as well as tailored support in drug development, medical affairs, pharmacovigilance, regulatory and medical writing during pre- and post-approval.

TranScrip Partners Hong Kong will be led by James Thorburn who has over 25 years’ experience in clinical research and development involving drugs and medical devices as well as a record of establishing contract research organisations both in the UK and his native Hong Kong. He will help support TranScrip’s continuing interests in the Asia-Pacific region, including China and India, and will be working closely with TranScrip Partners Australia.

TranScrip’s Managing Partner, Dr Flic Gabbay, said the establishment of the Hong Kong office is “the next step in our global strategy for growth and will consolidate our presence in Asia-Pacific, a region which we see as being highly significant with regard to pharmaceutical drug development and sales.”